Novo Nordisk, Lundbeck, Leo Pharma

The Danish pharmaceutical industry and TTIP

The Transatlantic Trade and Investment Partnership (TTIP) agreement currently being negotiated by the EU and the US is expected to lead to significant benefits for Denmark, and the pharmaceutical industry is an important driver in this. It is expected to account alone for up to 40 percent of the total expected increase in Danish exports and up to 20 percent of the total impact on Danish GDP arising from an ambitious TTIP agreement, targeting non-tariff barriers to transatlantic trade in pharmaceuticals.

The main conclusions of our study are

The study is commissioned by Novo Nordisk A/S, Lundbeck A/S, Leo Pharma A/S

Download